Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
The running back will put pen to paper on a four-year, $33.2 million extension. Hubbard's new deal will make him one of the highest-paid players in his position. On that note, here's a list of the top ...